Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEGF-A165-stimulated autologous adipose-derived mesenchymal stromal cells
- Development stage
- Unknown
- Lead developer
- Rigshospitalet
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
This investigational autologous cell therapy consists of adipose-derived mesenchymal stromal cells (ASCs) harvested from a patient's own abdominal fat. Developed by Rigshospitalet at the University of Copenhagen, the cells are culture-expanded and stimulated with vascular endothelial growth factor-A165 (VEGF-A165) to enhance their angiogenic potential. The therapy is administered via intramyocardial injections into ischemic but viable heart tissue. It is primarily intended for patients with chronic myocardial ischemia and refractory angina who have exhausted conventional revascularization options. The treatment aims to improve myocardial perfusion and cardiac function through paracrine signaling and the promotion of neovascularization.
- Other names
- autologous adipose-derived stromal cellsASCsadipose-derived mesenchymal stromal cellsMyStromalCell
Beyond the preview
Go deeper on VEGF-A165-stimulated autologous adipose-derived mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VEGF-A165-stimulated autologous adipose-derived mesenchymal stromal cells.